10-30-13 3:08 PM EDT | Email Article

SHANGHAI and TAIPEI, Oct. 30, 2013 /PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it had completed a cell culture capacity expansion, including two 2000L disposable bioreactors that are ready for cGMP manufacturing. Previously WuXi AppTec had built a state-of-the-art cGMP biologics manufacturing facility with two cell culture suites containing a 500L and a 1000L disposable bioreactor, respectively. As a result of this new expansion, WuXi AppTec operates the largest biologics facility with disposable bioreactors in China and the largest disposable bioreactor in the world. The facility has passed GMP audits from global clients and an audit by former U.S. FDA biologics inspectors. WuXi AppTec is now poised to support Phase III clinical manufacturing and initial commercial launch for therapeutic antibody and recombinant protein drugs. 

WuXi AppTec also announced completion of the first run of the 2000L disposable bioreactor using an NS0 mouse myeloma cell line for TaiMed Biologics' ibalizumab, a novel CD4 entry inhibitor for the treatment of HIV/AIDS infection. This event marks an important milestone in the global biologics manufacturing industry. Growing NS0 cells in disposable bioreactors entails significant technical challenges, and there are few reported cases of growing NS0 cells in large disposable bioreactors. Through intensive process research and development, WuXi AppTec reproduced in disposable bioreactors a manufacturing process originally implemented in traditional stainless steel bioreactors, with comparable process performance and product quality.

"Successful completion of our biologics facility expansion and the subsequent 2000L run mark important milestones in WuXi AppTec's mission of building first-class biologics manufacturing capabilities in China," said Dr. Ge Li, Chairman and Chief Executive Officer of WuXi AppTec.  "Although there is overcapacity in biologics manufacturing facilities globally, our biologics manufacturing facility is the only one in China that meets global cGMP standards. Through this expansion, we can quickly address increasing market demand for high-quality and cost-effective manufacturing of biologics. The first 2000L run also showcases our solid development and scale-up capabilities in mammalian cell culture. We continue to invest to build our integrated open-access biologics discovery, development, and manufacturing platform to serve our global clients and to play a pivotal role as the gateway for introducing biologics into the Chinese market."

"WuXi AppTec has made excellent progress in producing clinical-trial supplies for ibalizumab, an important new medicine for global patients," said Dr. James Chang, Chief Executive Officer of TaiMed Biologics. "We are delighted to have such a skilled and reputable manufacturing partner as we enter into late-phase trials of ibalizumab in the United States and Asia."

About WuXi PharmaTech

As a research-driven and customer-focused company, WuXi PharmaTech (Cayman) Inc. provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process.  WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D.  WuXi AppTec is the name for the operating subsidiaries of WuXi PharmaTech.  Please visit http://www.wuxiapptec.com.

About TaiMed Biologics

TaiMed Biologics, Inc. is a publicly held Taiwanese biotechnology company with the mission to discover, develop and deliver for the global market innovative medicines that help patients prevail over serious infectious diseases.  For more information, please visit http://www.taimedbiologics.com.

For more information, please contact:

Ronald Aldridge
Director of Investor Relations
WuXi PharmaTech

Aaron Shi
Associate Director of Corporate Communications
WuXi PharmaTech

James N. Chang, PhD
Chief Executive Officer
TaiMed Biologics
+1 949-769-6543 (USA)
+886-2-2655-8031 (Taiwan)

SOURCE WuXi PharmaTech (Cayman) Inc.

Add a Comment

News   More...

Securities related to this article
WuXi PharmaTech (Cayman), Inc. ADR View wx Stock Quote
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar

Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Content Partners
Morningstar - 2013/10/30 - WuXi AppTec Successfully Completes Its First 2000L Disposable Bioreactor Run Using an NS0 Cell Line, Marking an Industry Milestone
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Author |  Collection |  Interest |  Popularity

Previous: WuXi AppTec Receives CLIA Certification for its Genomics Clinical Laboratory  |  Next: WuXi Manufacturing Facility Passes FDA Inspection